Lewis Choi Takes the Helm as Chief Information Officer of Neurocrine Biosciences

Neurocrine Biosciences Welcomes Lewis Choi as Chief Information Officer

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has officially appointed Lewis Choi as its new Chief Information Officer, effective June 9, 2025. With an impressive career spanning 25 years in the fields of information technology and artificial intelligence, Choi is set to drive the company's strategic technology initiatives forward.

More than just a Leader

Lewis Choi brings to Neurocrine a wealth of experience, having built an impressive reputation as a leader in the healthcare technology sector. His track record highlights a profound ability to leverage technology to instigate both cultural and technological advancements. Matt Abernethy, the Chief Financial Officer of Neurocrine, expressed confidence in Choi's capabilities, emphasizing his history of successful transformation in global healthcare settings. "Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change," Abernethy noted.

At a time when the company is launching its innovative product CRENESSITY and expanding its existing treatment INGREZZA, Choi's appointment comes at a moment of significant growth and potential for Neurocrine. Abernethy stated, "As we launch CRENESSITY, grow INGREZZA, and advance our pipeline, he joins Neurocrine at an exciting time when advancements in technology will play a critical role in advancing our mission to help more patients."

A Visionary with Experience

Choi's impressive resume includes a 13-year tenure at Thermo Fisher Scientific, where he served in a variety of key positions, culminating in his role as Vice President of AI Automation and Data. His portfolio reflects his adeptness in global digital strategy, including spearheading innovative solutions across multiple markets. His previous roles spanned responsibilities such as Global Vice President of Digital Platforms, Engineering & Generative AI, Vice President of Digital Solutions for APAC and Emerging Markets, and more.

Before his accomplishments at Thermo Fisher, Choi held several IT positions at prominent firms, including Life Technologies, SysGroup Inc., Serene Corporation, ADP, and Corio, Inc. His academic foundation was established with a Bachelor of Arts degree from the University of California, Berkeley.

Transforming Through Technology

Upon his appointment, Choi expressed enthusiasm for joining Neurocrine at this pivotal junction. He stated, "I am excited to join Neurocrine at such a pivotal time for the company. I look forward to leveraging innovative IT and digital solutions to strengthen the business and support the teams who work tirelessly to discover, develop, and deliver critical treatments for patients."

Choi’s vision involves a comprehensive approach to intertwining cutting-edge technology with healthcare solutions. This aligns with Neurocrine's commitment to alleviating human suffering through scientifically backed advancements in treatment, particularly for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders.

Neurocrine’s Commitment to Innovation

Neurocrine Biosciences stands as a formidable player in the biopharmaceutical sector, embracing a mission to provide life-changing treatments. Their diverse portfolio features FDA-approved medications targeting various conditions, including tardive dyskinesia, chorea related to Huntington's disease, and more. Furthermore, their robust pipeline promises numerous compounds in late-phase clinical development.

For over three decades, Neurocrine has applied its insights into neuroscience, driving progress in treating complex health issues. Choi’s leadership in information technology is anticipated to enhance the company's strategic growth and potency in the pharmaceutical industry. As the healthcare landscape evolves, Choi's role could act as a catalyst for the innovative applications necessary to meet patient needs effectively.

For more information about Neurocrine Biosciences and their ongoing projects, follow the company on LinkedIn, X, and Facebook.